BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20215584)

  • 1. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E; Gregory L; Teague J; Myatt J; Hammond C; Poucher SM; Jones HB
    Toxicol Pathol; 2010 Apr; 38(3):393-401. PubMed ID: 20215584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats.
    Docsa T; Czifrák K; Hüse C; Somsák L; Gergely P
    Mol Med Rep; 2011; 4(3):477-81. PubMed ID: 21468595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models.
    Furukawa S; Murakami K; Nishikawa M; Nakayama O; Hino M
    J Antibiot (Tokyo); 2005 Aug; 58(8):503-6. PubMed ID: 16266121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen phosphorylase inhibitors.
    Henke BR; Sparks SM
    Mini Rev Med Chem; 2006 Aug; 6(8):845-57. PubMed ID: 16918491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model.
    Sickmann HM; Waagepetersen HS; Schousboe A; Benie AJ; Bouman SD
    Neurochem Int; 2012 Feb; 60(3):267-75. PubMed ID: 22244844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog.
    Edgerton DS; Cardin S; Neal D; Farmer B; Lautz M; Pan C; Cherrington AD
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E510-22. PubMed ID: 14644767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
    van Poelje PD; Potter SC; Chandramouli VC; Landau BR; Dang Q; Erion MD
    Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration.
    Taguchi T; Yamashita E; Mizutani T; Nakajima H; Yabuuchi M; Asano N; Miwa I
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E534-40. PubMed ID: 15536204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D; Kónya B; Chajistamatiou AS; Chrysina ED; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Somsák L; Docsa T; Gergely P; Praly JP; Azay-Milhau J; Vidal S
    Eur J Med Chem; 2016 Jan; 108():444-454. PubMed ID: 26708111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.
    Freeman S; Bartlett JB; Convey G; Hardern I; Teague JL; Loxham SJ; Allen JM; Poucher SM; Charles AD
    Br J Pharmacol; 2006 Nov; 149(6):775-85. PubMed ID: 17016495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rapid onset of hyperglycaemia in ZDF rats was associated with a widespread alteration of metabolic proteins implicated in glucose metabolism in the heart.
    Lajoie C; Béliveau L; Trudeau F; Lavoie N; Massicotte G; Gagnon S; Calderone A
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1205-13. PubMed ID: 17218985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.
    Fujimoto Y; Torres TP; Donahue EP; Shiota M
    Diabetes; 2006 Sep; 55(9):2479-90. PubMed ID: 16936196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing mechanisms of hepatic glucose overproduction in triiodothyronine-treated rats vs. Zucker diabetic fatty rats by NMR analysis of plasma glucose.
    Jin ES; Burgess SC; Merritt ME; Sherry AD; Malloy CR
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E654-62. PubMed ID: 15562253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
    Yoshida T; Okuno A; Izumi M; Takahashi K; Hagisawa Y; Ohsumi J; Fujiwara T
    Eur J Pharmacol; 2008 Dec; 601(1-3):192-7. PubMed ID: 19014931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain.
    Scalia R; Gong Y; Berzins B; Zhao LJ; Sharma K
    Diabetes; 2007 Jul; 56(7):1842-9. PubMed ID: 17446533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon challenge in the rat: a robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy.
    Loxham SJ; Teague J; Poucher SM; De Schoolmeester J; Turnbull AV; Carey F
    J Pharmacol Toxicol Methods; 2007; 55(1):71-7. PubMed ID: 16713718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hepatic targets for glycaemic control in diabetes.
    Agius L
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA; Banker P; Bickett DM; Boucheron JA; Carter HL; Clancy DC; Cooper JP; Dickerson SH; Garrido DM; Nolte RT; Peat AJ; Sheckler LR; Sparks SM; Tavares FX; Wang L; Wang TY; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1177-82. PubMed ID: 19138846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.